The role of mTORC2 in reprogramming cancer cell metabolism

mTORC2在重编程癌细胞代谢中的作用

• 批准号: 9174889
• 负责人: PAUL S MISCHEL
• 金额: $ 34.48万
• 依托单位: LUDWIG INSTITUTE FOR CANCER RES LTD
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-15 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9174889
• 关键词: ATP Citrate (pro-S)-Lyase; Acetates; Acetyl-CoA Carboxylase; Acetylation; Acyltransferase; Automobile Driving; Bioavailable; Biochemical; Brain; Cancer Etiology; Cells; Ceramides; Chemicals; Complex; Data; Development; Drug Kinetics; Drug resistance; Enzymes; FRAP1 gene; Fatty Acids; Fatty-acid synthase; Formulation; Genetic; Glioblastoma; Glucocorticoids; Glucose; Glutamine; Goals; Grant; Growth; Growth Factor Receptors; Histones; Image; Implant; Knowledge; Label; Lipid Synthesis Pathway; Lipids; Liquid Chromatography; Malignant Neoplasms; Malignant neoplasm of brain; Mediator of activation protein; Membrane; Metabolic; Metabolic Pathway; Metabolism; Modeling; Molecular; Mus; Mutation; Nutrient; Oncogenic; Palmitates; Pathway interactions; Patients; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Phosphotransferases; Plasma; Process; Property; Proteins; Receptor Signaling; Research; Resistance; Role; Serum; Signal Pathway; Signal Transduction; Signaling Molecule; Specific qualifier value; Sphingolipids; Testing; Therapeutic; base; cancer cell; cell growth; design; effective therapy; fluorescence molecular tomography; genome editing; in vivo; inhibitor/antagonist; knock-down; lipid biosynthesis; lipid metabolism; membrane biogenesis; neoplastic cell; novel therapeutics; overexpression; research study; site-1 protease; small molecule; tandem mass spectrometry; transcription factor; tumor; tumor growth; tumor metabolism; uptake

The role of mTORC2 in cancer cell metabolism PROJECT SUMMARY Metabolic reprogramming is a hallmark of cancer. Mutations in growth factor receptor signaling pathways promote tumor growth by altering the uptake and utilization of nutrients. De novo synthesis of lipids is a critical aspect of this process, providing necessary lipids for membrane biogenesis and signal transduction. Currently, there is a major gap in our knowledge about how oncogenic signaling regulates the synthesis of specific lipids to cause tumor growth, and by what mechanisms. this RO1 grant (NS 73831), we have demonstrated that Through studies supported by the first five years of the mechanistic target of rapamycin (mTORC2), a critical mediator of growth factor receptor signaling, reprograms tumor cellular metabolism, potently stimulating the growth of the highly lethal brain cancer glioblastoma (GBM) and causing resistance to almost all current treatments. Specifically, our preliminary studies indicate that mTORC2 drives nutrient flux into lipogenic pathways and boosts the synthesis of specific lipids to drive tumor growth by regulating the levels and/or activities of key rate limiting enzymes. These data reveal a landscape of new, potentially druggable targets. However, before these mechanisms can be applied to inform the development of new therapies, a number of urgent questions must be answered. How does mTORC2 regulate GBM nutrient uptake and utilization and shift it towards the synthesis of specific lipids in cancer? What are the signaling, biochemical and transcriptional mechanisms and how do they drive tumor growth and drug resistance? Are they druggable? This proposal is designed to test the hypothesis that mTORC2 promotes GBM growth and drug resistance by driving lipogenesis and remodeling the composition of specific signaling lipids. Our goal is to understand the mechanisms most critical for breaking down a major barrier to developing more effective treatments. In aim 1, we propose a set of experiments that will extend our metabolic analyses into patient-derived GBMs in vivo, to determine how mTORC2 controls the synthesis of specific phospholipids and sphingolipids to drive GBM growth and drug resistance, and to identify the signaling, biochemical and transcriptional mechanisms by which mTORC2 controls the key enzymes that regulate this process. In aim 2, we will determine how mTORC2 controls the uptake and utilization of nutrients towards the synthesis of these specific lipids. In aim 3, we will identify and develop CNS-penetrant small molecules that target mTORC2-dependent metabolic reprogramming and evaluate their therapeutic potential. The proposed studies will generate a deeper understanding of the role of mTORC2 in cancer cell metabolism and will generate a landscape of previously unappreciated metabolic vulnerabilities that can be targeted by brain penetrant compounds, potentially leading to better GBM treatments

mTORC 2在癌细胞代谢中的作用 项目摘要 代谢重编程是癌症的标志。生长因子受体信号通路的突变 通过改变营养物质的吸收和利用促进肿瘤生长。脂质的从头合成是一个关键的 这一过程的一个方面，提供必要的脂质 膜生物发生和信号转导。 目前， 我们对致癌信号如何调节特异性DNA合成的认识存在很大差距， 脂质导致肿瘤生长，以及通过什么机制。 在此RO 1补助金（NS 73831）中，我们已经证明， 通过前五年支持的研究， 雷帕霉素的机制靶点（mTORC 2）， 生长因子受体信号传导的关键介质，重新编程肿瘤细胞代谢，有效刺激 高致命性脑癌胶质母细胞瘤（GBM）的生长，并导致对几乎所有电流的抵抗， 治疗。具体来说，我们的初步研究表明，mTORC 2驱动营养通量进入脂肪生成， 途径，并促进特定脂质的合成，通过调节水平和/或 关键限速酶的活性。这些数据揭示了一个新的、潜在的药物靶点。 然而，在这些机制可以应用于新疗法的开发之前， 迫切的问题必须得到回答。mTORC 2如何调节GBM营养吸收和利用， 转移到癌症中特定脂质的合成上什么是信号，生物化学和 转录机制以及它们如何驱动肿瘤生长和耐药性？他们是药吗？ 该提议旨在检验mTORC 2通过以下方式促进GBM生长和耐药性的假设： 驱动脂肪生成和重塑特定信号脂质的组成。我们的目标是了解 对于打破开发更有效治疗方法的主要障碍至关重要。在目标1中， 我们提出了一组实验，将我们的代谢分析扩展到体内患者源性GBM， 确定mTORC 2如何控制特定磷脂和鞘脂的合成以驱动GBM 生长和耐药性，并确定信号，生化和转录机制， mTORC 2控制着调节这一过程的关键酶。在目标2中，我们将确定mTORC 2 控制营养素的吸收和利用，以合成这些特定的脂质。在目标3中，我们 鉴定和开发靶向mTORC 2依赖性代谢的CNS渗透小分子 重新编程并评估其治疗潜力。拟议的研究将产生更深层次的 了解mTORC 2在癌细胞代谢中的作用，并将产生一个以前的景观， 未被重视的代谢弱点，可以通过大脑渗透化合物的目标，潜在地导致 更好的GBM治疗